Horizon Investments LLC Has $92,000 Stock Position in Alkermes plc $ALKS

Horizon Investments LLC lowered its holdings in shares of Alkermes plc (NASDAQ:ALKS) by 92.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,296 shares of the company’s stock after selling 39,706 shares during the period. Horizon Investments LLC’s holdings in Alkermes were worth $92,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Assetmark Inc. increased its holdings in Alkermes by 933.8% in the 3rd quarter. Assetmark Inc. now owns 827 shares of the company’s stock worth $25,000 after purchasing an additional 747 shares in the last quarter. Johnson Financial Group Inc. acquired a new position in Alkermes in the 3rd quarter worth about $31,000. Hantz Financial Services Inc. increased its holdings in Alkermes by 395.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,239 shares of the company’s stock worth $37,000 after purchasing an additional 989 shares in the last quarter. Salomon & Ludwin LLC increased its holdings in Alkermes by 115.6% in the 4th quarter. Salomon & Ludwin LLC now owns 1,244 shares of the company’s stock worth $35,000 after purchasing an additional 667 shares in the last quarter. Finally, Osaic Holdings Inc. increased its holdings in Alkermes by 56.4% in the 2nd quarter. Osaic Holdings Inc. now owns 1,945 shares of the company’s stock worth $56,000 after purchasing an additional 701 shares in the last quarter. Institutional investors and hedge funds own 95.21% of the company’s stock.

Wall Street Analyst Weigh In

ALKS has been the subject of a number of recent research reports. Wells Fargo & Company upped their target price on Alkermes from $43.00 to $44.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Needham & Company LLC upped their target price on Alkermes from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Piper Sandler lowered their target price on Alkermes from $45.00 to $43.00 and set an “overweight” rating for the company in a report on Tuesday, March 24th. UBS Group upped their target price on Alkermes from $42.00 to $48.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Wall Street Zen cut Alkermes from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.21.

Alkermes Price Performance

Shares of Alkermes stock opened at $34.99 on Monday. Alkermes plc has a one year low of $25.17 and a one year high of $36.60. The company has a debt-to-equity ratio of 0.85, a current ratio of 2.27 and a quick ratio of 1.70. The stock’s 50-day moving average is $31.63 and its 200 day moving average is $31.04. The firm has a market cap of $5.83 billion, a price-to-earnings ratio of 38.88 and a beta of 0.31.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings results on Saturday, February 14th. The company reported $0.29 earnings per share (EPS) for the quarter. The business had revenue of $384.55 million for the quarter. Alkermes had a return on equity of 9.26% and a net margin of 9.78%. Equities research analysts anticipate that Alkermes plc will post -0.62 EPS for the current year.

Insiders Place Their Bets

In other Alkermes news, SVP Christian Todd Nichols sold 6,000 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $30.00, for a total value of $180,000.00. Following the transaction, the senior vice president owned 109,769 shares in the company, valued at approximately $3,293,070. This represents a 5.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP David Joseph Gaffin sold 2,034 shares of the stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $33.20, for a total value of $67,528.80. Following the completion of the transaction, the executive vice president owned 231,558 shares in the company, valued at approximately $7,687,725.60. The trade was a 0.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 39,102 shares of company stock worth $1,265,090. Corporate insiders own 4.59% of the company’s stock.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.